x

Posted 22 September, 2022

iSpecimen Inc. appointed Tracy Curley as new CEO

Nasdaq:ISPC appointed new Chief Executive Officer Tracy Curley in a 8-K filed on 22 September, 2022.


  The Board appointed Tracy Curley, who currently serves as the Chief Financial Officer and Treasurer of the Company, as Interim Chief Executive Officer of the Company, effective immediately upon Dr. Ianelli's no longer serving as Chief Executive Officer and President of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of iSpecimen Inc.
None • None
iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in July 2009 and is headquartered in Lexington, MA.
Market Cap
$4.25M
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On September 19, 2022, the Board of Directors (the "Board") of iSpecimen Inc. (the "Company") received a notice of departure from Christopher Ianelli to vacate the positions of Chief Executive Officer and President of the Company, effective as of October 24, 2022, as a result of the non-renewal of his Executive Employment Agreement dated June 21, 2021.


On September 20, 2022, the Board received a similar notice of departure from Jill Mullan to vacate the position of Chief Operating Officer of the Company, effective as of October 24, 2022, as a result of the non-renewal of her Executive Employment Agreement dated June 21, 2021.


On September 21, 2022, pursuant to the mutual agreement of Dr. Ianelli and the Board, Dr. Ianelli vacated his positions as Chief Executive Officer and President of the Company. The Board appointed Tracy Curley, who currently serves as the Chief Financial Officer and Treasurer of the Company, as Interim Chief Executive Officer of the Company, effective immediately upon Dr. Ianelli's no longer serving as Chief Executive Officer and President of the Company. Ms. Curley will serve as Interim Chief Executive Officer until the Company appoints a new Chief Executive Officer and will also continue to serve as the Chief Financial Officer of the Company. The Company is currently negotiating a new Executive Employment Agreement with Ms. Curley in connection with her services as Interim Chief Executive Officer and Chief Financial Officer of the Company. Upon execution of the Executive Employment Agreement by the Company and Ms. Curley, the Company intends to file a subsequent Current Report on Form 8-K with the Securities and Exchange Commission ("SEC") to report the financial and other terms thereunder and will also file a copy of the Executive Employment Agreement as an exhibit to such subsequently filed Current Report on Form 8-K.


Dr. Ianelli and Ms. Mullan have both agreed to continue to provide services as employees, on behalf of the Company through the termination of their employment with the Company on October 24, 2022, in order to assure a smooth transition in the Company's management.


The Company is currently negotiating Separation Agreements with each of Dr. Ianelli and Ms. Mullan, which are expected to include the financial and other terms of each of their terminations as executive officers of the Company. The Company intends to file a subsequent Current Report on Form 8-K with the SEC to report the execution of the Separation Agreements with Dr. Ianelli and Ms. Mullan and the financial and other terms thereunder, Copies of the Separation Agreements will be filed as exhibits to such subsequently filed Current Report on Form 8-K.